Health Catalyst, Inc. (HCAT) SEC Filings & Earnings Calls
EquiReason read 27 Health Catalyst, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Appointment of Tami Reller to the Board of Directors, effective October 1, 2026, filling a newly created seat and serving as audit chair and compensation committee member. The appo.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 127.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 2026SC 13D/APalogic Value Management disclosed a 7.1% activist stake in Health Catalyst and sent a letter requesting a clear business plan and enhanced disclosure.open
Figures in the filing · each found in the filing text
| Beneficial ownership · 2026-09-04 | 5,374,949 | |
| Ownership percentage · 2026-09-04 | 7.1% |
Risks flagged
Activist pressure may lead to strategic changes
“Palogic Value Management requested that the Board of Directors of the Issuer provide investors a clear, forward-looking business plan.”
6 Aug 20268-K · 1.02, 2.01, 2.02, 7.01Health Catalyst exceeded high end of revenue guidance and midpoint of adjusted EBITDA guidance in Q2 2026; also repaid credit facility debt and completed Vitalware divestiture.open
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $70M | -13% y/y |
| Gross profit · Q2-2026 | $28M | -8% y/y |
| Gross margin · Q2-2026 | 40.0% | |
| Net loss · Q2-2026 | $-41M | +1% y/y |
| Adjusted EBITDA · Q2-2026 | $10M | +6% y/y |
| Adjusted Gross Profit · Q2-2026 | $36M | -10% y/y |
| Adjusted Gross Margin · Q2-2026 | 51.0% |
Guidance
Q3 2026 revenue $55-56M, Adjusted EBITDA $0-0.5M; FY2026 revenue $246-249M, Adjusted EBITDA $18-18.5M
Guidance provided for Q3 and FY2026; revenue and adjusted EBITDA ranges consistent with prior expectations.
Risks flagged
Revenue decline of 13% YoY; divestiture impact and potential ongoing headwinds.
“Total revenue $70,487 ... (13)%”
6 Aug 202610-QHCAT reports ongoing demand weakness from DOS-to-Ignite migration, multiple restructuring plans, and goodwill impairments, with negative impact from Vitalware divestiture.earningsopen
Figures in the filing · each found in the filing text
| Revenue from three largest clients (2025) · FY2025 | 13.6% | |
| Revenue from three largest clients (2024) · FY2024 | 13.8% | |
| Goodwill impairment charge (2025) · FY2025 | $105M | |
| Goodwill impairment charge (2026) · FY2026 | $96M |
Guidance
Future total revenue, gross profit, net income, Adjusted Gross Profit, and Adjusted EBITDA will be negatively impacted due to Vitalware divestiture
Management expects negative impact from Vitalware divestiture and ongoing churn from Ignite migration, with no specific guidance range provided.
Risks flagged
Client concentration risk
“Our three largest clients during 2025 comprised 5.7%, 4.4%, and 3.5% of our revenue, or 13.6% in the aggregate.” · word for word
Restructuring execution risk
“Project Nexus and any other or future restructuring or cost optimizing efforts may disrupt our operations and performance, and could lead to dissatisfaction or a reduction in morale among our workforce, attrition, or otherwise harm our relationship with our team members.” · word for word
Ignite migration churn risk
“We have also continued to experience churn or down-selling particularly related to the migration of our DOS platform clients to our Ignite platform, and may further experience churn or down-selling as a result of the Vitalware Transaction.” · word for word
Macroeconomic and funding cut risk
“These uncertainties in our end market could cause potential delays in client decisions.” · word for word
8 Jun 2026SC 13D/AWhetstone Capital Advisors reports 4.5% passive/hedged stake in Health Catalyst via funds, with long options and short positions, no new activist intent.open
Risks flagged
Potential activist or hedging activity
“Item 4. Purpose of Transaction See the Schedule 13D.” · word for word
8 Jun 2026SC 13D/AWhetstone Capital Advisors reports 4.5% passive/hedged stake in Health Catalyst via funds, with long options and short positions, no new activist intent.open
Risks flagged
Potential activist or hedging activity
“Item 4. Purpose of Transaction See the Schedule 13D.” · word for word
3 Jun 2026DEF 14AProxy statement filed for 2026 Annual Meeting; includes proposals to elect directors, ratify auditor, approve executive compensation, and declassify the board.open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $311M | +1% y/y |
| Technology Revenue · Technology · FY2025 | $208M | +7% y/y |
| Professional Services Revenue · Professional Services · FY2025 | $103M | -8% y/y |
| GAAP Net Loss · FY2025 | $178M | +156% y/y |
| Adjusted EBITDA · FY2025 | $41M | +59% y/y |
| Adjusted Net Income · FY2025 | $13M | -23% y/y |
| Platform Clients · FY2025 | 162 | +25% y/y |
| Net New Platform Clients · FY2025 | 32 | |
| Goodwill Impairment · FY2025 | $105M | |
| Adjusted EBITDA Margin · FY2025 | 13.0% |
Risks flagged
Goodwill Impairment Risk
“The increased net loss in 2025 compared to 2024 is largely driven by $105.4 million of goodwill impairment, which is primarily due to overall declines in our stock price and market capitalization.” · word for word
Revenue Growth Deceleration
“Total revenue was $311.1 million, an increase of 1% year-over-year.” · word for word
Professional Services Revenue Decline
“professional services revenue was $102.9 million, a decrease of 8% year-over-year.” · word for word
Stock Price Decline
“The increased net loss in 2025 compared to 2024 is largely driven by $105.4 million of goodwill impairment, which is primarily due to overall declines in our stock price and market capitalization.” · word for word
11 May 20268-K · 2.02Health Catalyst Q1 2026 revenue $70.8M (-11% YoY), adjusted EBITDA $9.1M (+46% YoY), guides Q2 and FY26; strategic reset underway.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $71M | -11% y/y |
| Adjusted EBITDA · Q1-2026 | $9M | +46% y/y |
| Net Loss · Q1-2026 | $-111M | +368% y/y |
| Gross Profit · Q1-2026 | $28M | -3% y/y |
| Gross Margin · Q1-2026 | 39.0% | |
| Adjusted Gross Profit · Q1-2026 | $36M | -7% y/y |
| Adjusted Gross Margin · Q1-2026 | 51.0% |
Guidance
Q2 2026 revenue $68M-$70M, adjusted EBITDA $9M-$10M; FY26 revenue $260M-$265M, adjusted EBITDA $30M-$33M
New guidance issued for Q2 and FY26; revenue decline expected to continue but adjusted EBITDA growth indicates margin focus.
Risks flagged
Revenue decline of 11% YoY; client churn and down-sell risk from DOS to Ignite migration.
“Total revenue down 11%; at-risk ARR may churn or down-sell in 2026 and 2027.”
Net loss widened to $(111.0)M from $(23.7)M; potential impairment or restructuring charges.
“Net loss $(111.0)M vs $(23.7)M, down 368%.”
11 May 202610-QHealth Catalyst reported Q1 2026 revenue of $70.8M, down 11% YoY, with a net loss of $111M including a $95.5M goodwill impairment, but Adjusted EBITDA improved to $9.1M.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $71M | -11% y/y |
| Technology Revenue · Technology · Q1-2026 | $49M | -4% y/y |
| Professional Services Revenue · Professional Services · Q1-2026 | $21M | -24% y/y |
| Gross Margin · Q1-2026 | 39.0% | |
| Adjusted EBITDA · Q1-2026 | $9M | |
| Goodwill Impairment · Q1-2026 | $96M | |
| Net Loss · Q1-2026 | $-111M |
Guidance
Expects near-term revenue headwinds from Medicaid cuts and platform migration; expects Adjusted EBITDA to improve long-term but near-term growth slower.
Management expects near-term revenue pressure from Medicaid cuts and platform migration, but sees margin expansion from restructuring. No specific numeric guidance provided.
Risks flagged
Platform Migration Churn
“We have been notified of $12.5 million of ARR down-sell and churn and estimate we have $52.0 million of at risk ARR related to the DOS to Ignite migration.” · word for word
Medicaid Funding Cuts
“On July 4, 2025, President Trump signed the OBBBA into law, which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years and will create additional financial strain for many of our clients and prospective clients.” · word for word
Goodwill Impairment Risk
“Further declines in our stock price and market capitalization could result in further impairment charges, which could adversely affect our results of operations.” · word for word
30 Apr 202610-K/AThis 10-K/A amendment only contains Part III executive compensation and governance disclosures; no business, MD&A, risk factors, or guidance sections. Extracted signals are limited to compensation-related performance metrics and management changes.open
Risks flagged
Executive turnover risk
“Daniel Burton retired as Chief Executive Officer effective February 12, 2026; multiple board resignations.”
Goodwill impairment risk
“Impairment of goodwill and intangible assets was recognized... $110,223 thousand.”
Revenue growth shortfall
“Revenue Growth Rate Achievement... Actual Result 1.5% vs. Target 10.0%.”
27 Apr 20268-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Workforce reduction may indicate underlying operational or financial challenges, though framed as strategic transformation.
“The Company expects this initiative to reduce its global workforce by approximately 9% and eliminate approximately 100 additional open, budgeted headcount positions... representing a meaningful reduction in the Company's cost structure.”
12 Mar 20268-K · 2.02HCAT reports FY2025 total revenue $311.1M (+1% YoY), Adjusted EBITDA $41.4M (+59% YoY); Q1 2026 guidance: revenue $68-70M, Adj. EBITDA $7-8M; no FY2026 guidance due to CEO transition review.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $311M | +1% y/y |
| Adjusted EBITDA · FY2025 | $41M | +59% y/y |
| Gross Margin · FY2025 | 38.7% | |
| Adjusted Gross Margin · FY2025 | 51.1% | |
| Net Loss · FY2025 | $-178M | +156% y/y |
| Platform Clients · FY2025 | 162 | +25% y/y |
| Dollar-based Retention Rate · FY2025 | 93.0% | |
| Cash and Cash Equivalents · Q4-2025 | $51M | -80% y/y |
| Short-term Investments · Q4-2025 | $45M | -68% y/y |
Guidance
Q1 2026 revenue $68-70M; Q1 2026 Adjusted EBITDA $7-8M
Q1 2026 guidance provided; no FY2026 guidance due to CEO transition; margin improvement expected.
Risks flagged
Significant cash burn: cash and investments declined from $392M to $95.7M; net loss widened to $178M.
“Cash and cash equivalents $50.8M (down from $249.6M); short-term investments $44.9M (down from $142.4M); net loss $(178.0)M”
Client retention declining: dollar-based retention rate dropped to 93% from 102%, indicating churn or downsell.
“Dollar-based Retention Rate 93% vs 102%”
CEO transition and lack of FY2026 guidance create strategic uncertainty.
“We are not providing forward-looking guidance for the full year of 2026 at this time due to an ongoing internal strategic and operational review in connection with our CEO transition.” · word for word
12 Mar 202610-KAnnual 10-K filing with no explicit beat or miss; reports client metrics and retention rates.earningsopen
Figures in the filing · each found in the filing text
| Platform Clients · FY2025 | 162 | |
| App Clients · FY2025 | 1,000 | |
| Dollar-based Retention Rate · FY2025 | 93.0% | |
| Documented Improvements · FY2025 | 2,000 |
Risks flagged
Competitive pressure from larger companies
“many of our competitors and potential competitors have significantly greater financial, technological, and other resources and name recognition than we do” · word for word
Regulatory compliance costs
“Our business is subject to extensive, complex, and rapidly changing federal and state laws and regulations” · word for word
12 Jan 20268-K · 2.02Preliminary FY2025 revenue slightly above ~$310M guidance, Adj. EBITDA ~$41M in line, net new Platform Clients 32 vs target 30, Dollar-Based Retention Rate 93%. Guidance for 2026 bookings growth.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $310M | |
| Adjusted EBITDA · FY2025 | $41M | |
| Net new Platform Clients · FY2025 | 32 | |
| Dollar-Based Retention Rate · FY2025 | 93.0% |
Guidance
FY2025 revenue slightly above ~$310M; Adj. EBITDA ~$41M; FY2026 bookings expected to exceed 2025.
Preliminary FY2025 results slightly beat revenue guidance, Adj. EBITDA in line, client additions ahead of target. 2026 bookings expected to grow, with cost optimization via AI and India resourcing.
Risks flagged
Preliminary results subject to change upon completion of audit; potential adjustments.
“These preliminary unaudited estimated results are subject to change upon completion of the Company’s accounting and annual audit procedures and are therefore subject to adjustment.” · word for word
Ignite migration timeline adjusted; some clients prefer to remain on DOS, posing retention risk.
“We have adjusted our timeline and approach to be more client-centric, recognizing that some organizations prefer to remain on DOS for the near to medium term.” · word for word
10 Nov 20258-K · 2.02Health Catalyst reported Q3 2025 revenue of $76.3M and Adjusted EBITDA of $12.0M, beating guidance on both measures. Gross margin improved to 39% from 36% YoY. Full-year 2025 guidance reaffirmed.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $76M | -0% y/y |
| Gross profit · Q3-2025 | $30M | +8% y/y |
| Gross margin · Q3-2025 | 39.0% | |
| Net loss · Q3-2025 | $-22M | -51% y/y |
| Adjusted Gross Profit · Q3-2025 | $40M | +11% y/y |
| Adjusted Gross Margin · Q3-2025 | 53.0% | |
| Adjusted EBITDA · Q3-2025 | $12M | +64% y/y |
Guidance
Q4 2025: total revenue ~$73.5M, Adjusted EBITDA ~$13.4M; FY2025: total revenue ~$310M, Adjusted EBITDA ~$41M
Guidance reaffirmed with Q4 and full-year targets consistent with prior outlook; management expresses confidence in sustained performance.
Risks flagged
Revenue flat YoY, indicating potential market saturation or competitive pressure.
“Total revenue $76,323K vs $76,353K, essentially flat”
Net loss widened to $22.2M from $14.7M, though partly due to non-cash items.
“Net loss $(22,229)K vs $(14,726)K, a 51% increase”
10 Nov 202510-QNo material event; filing is a routine quarterly risk factor update with no specific earnings or guidance event.open
Risks flagged
Client concentration risk
“Our three largest clients during 2024 comprised 5.5%, 4.4%, and 3.9% of our revenue, or 13.8% in the aggregate.” · word for word
Platform migration execution risk
“the migration of existing clients using our DOS Solution to Health Catalyst Ignite involves risk and may cause disruptions to our Solution, difficulties as clients acclimate to a new platform, or other challenges that could impair our clients’ use of our technology, any of which could lead to client dissatisfaction, lower revenue, and non-renewals.” · word for word
Macroeconomic and funding cuts risk
“Recent macroeconomic challenges (including high inflationary and/or high interest rate environments, uncertainty with tariffs, cuts in Medicaid and research funding, or market volatility and measures taken in response thereto), and the tight labor market continue to adversely affect workforces, organizations, governments, clients, economies, and financial ma” · word for word
Health Catalyst, Inc. — questions
- What did Health Catalyst, Inc. file recently?
- 27 SEC filings in the last 12 months. Latest: 8-K on 2026-09-14 — Appointment of Tami Reller to the Board of Directors, effective October 1, 2026, filling a newly created seat and serving as audit chair and compensation committee member. The appointment is part of a board expansion and follows the naming
Every figure on this page comes from Health Catalyst, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.